UnitedHealth Stock Soars on Medicare Advantage Rate
UnitedHealth stock jumped after CMS finalized a higher Medicare Advantage rate, easing a policy overhang and boosting analyst targets and sector flows.
KEY TAKEAWAYS
- CMS finalized a 2.5% Medicare Advantage rate increase for 2027, easing a major policy overhang.
- UnitedHealth shares rose about 8.1% and prompted same-day analyst price target increases.
- Q1 2026 earnings on April 21 will test repricing effectiveness and margin recovery.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
UnitedHealth Group (UNH) stock jumped on April 7, 2026, after the Centers for Medicare & Medicaid Services finalized a larger-than-proposed increase to 2027 Medicare Advantage payment rates, easing a policy overhang and improving margin visibility for the company's largest business.
CMS Rate Finalization Lifts Stock and Spurs Analyst Upgrades
The Centers for Medicare & Medicaid Services finalized a 2.48% increase in Medicare Advantage payment rates for 2027, reversing a January proposal that had sought only a 0.09% rise. The move signals a more supportive stance from the Trump administration and CMS Administrator Dr. Mehmet Oz.
UnitedHealth shares rose about 8% intraday to $304.09, adding billions to the company's market value. Peers including Humana and Elevance Health also rallied. Analysts revised price targets the same day, widening the Street range to roughly $330–$411 and lifting the consensus midpoint to about $357.81. Raymond James upgraded the stock to Outperform with a $330 target, Bernstein raised its target to $411, Bank of America moved its target to $337, and UBS reiterated a $410 target.
Outlook: Margins, Membership, and Legal Risks
UnitedHealth reported full-year 2025 revenue of $113.2 billion, slightly below the $113.7 billion consensus. Adjusted EPS for 2025 was $16.35, with management guiding 2026 adjusted EPS above $17.75, implying at least 8.6% growth. The company posted Q4 2025 EPS of $2.11 and EBITDA of $23.3 billion for 2025, down from $36.3 billion in 2023. UnitedHealth reiterated long-term EPS growth of 13%–16% alongside an 11.0% historical revenue compound annual growth rate. Tim Noel, CEO of UnitedHealthcare, said on the Q4 2025 earnings call, "Our 2026 approach favored margin recovery over any specific membership targets."
The medical care ratio (MCR), a measure of medical costs as a percentage of revenue, was 89.1% in 2025. Management guided to an 88.8% MCR for 2026, indicating continued cost pressure despite the rate increase.
UnitedHealthcare expects Medicare Advantage membership to decline by about 1.3–1.4 million in 2026. Repricing of its book was roughly 90% complete heading into the year, with the company targeting double-digit operating-earnings growth in that segment as repriced business lapses.
Optum Health swung to a $278 million operating loss in 2025 from about $7.8 billion of operating income in 2024. Optum's risk revenue runs near $58 billion at just under a 1% margin, while its non-capitation businesses total about $33 billion at mid-single-digit EBIT margins. Restructuring and a $623 million premium-deficiency reserve amortization have weighed on margin visibility.
Regulatory risks remain. The Department of Justice continues criminal and civil investigations into Medicare Advantage billing practices, focusing on whether patient diagnoses were inflated to secure higher government reimbursements. No resolution timeline has been disclosed.
Investors will get a near-term read on repricing and cost trends when UnitedHealth reports Q1 2026 results on April 21, 2026, a critical test of whether rate gains and repricing can outpace elevated medical costs.
